Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2014

2014

  • 2014 - 11 - 24

    The Menarini Group New Molecule Against Lymphomas And Solid Tumors

    Researchers present a new potential "weapon" for the destruction of tumour cells. Its name is MEN1309 and this new antibody is currently being studied by researchers at Menarini and Oxford Bio Therapeutics (OBT) against Non Hodgkin's lymphomas and solid tumours.
  • 2014 - 06 - 19

    Menarini One of the Top Ten Most Patient Friendly Companies

    2014 - An independent Corporate Reputation Survey of Pharma Companies, including 800 patient groups in 43 countries worldwide, ranked Menarini amongst the world's top ten Pharmaceutical companies closest to patients' needs. Menarini Climbs Up the Ranking to be Amongst Top Ten Companies Considered the Most "Patient Friendly"
  • 2014 - 03 - 06

    Three Visiting Experts Urge Women to Get Their Partners Treated for Premature Ejaculation

    A recent 2013 Asia-Pacific Sexual Behaviours and Satisfaction Survey[ii] revealed that 61% of men and 39% of women in Singapore believe that the man's ability to control when to ejaculate is critical to achieving mutual sexual satisfaction, and the desired intimacy of successful relationships.
  • 2014 - 02 - 13

    Moberg Pharma and Menarini Extend Distribution Agreement for Kersal Nail to South East Asia

    Singapore - 14 February 2014 – Moberg Pharma AB (OMX: MOB) and Menarini Asia-Pacific, a member of the Menarini Group are pleased to announce that Menarini Asia-Pacific has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries.